SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) · doi:10.1101/2021.01.15.426911 · Cited by 1,354

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Wu, K., Werner, A. P., Moliva, J. I., Koch, M., Choi, A., Stewart-Jones, G. B. E., Bennett, H., Boyoglu-Barnum, S., Shi, W., Graham, B. S., et al. (2021) · doi:10.1101/2021.01.25.427948 · Cited by 419

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human seraPreprint

Rathnasinghe, R., Jangra, S., Čupić, A., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., Mena, I., Vrieze, J. D., et al. (2021) · medRxiv · doi:10.1101/2021.01.19.21249592 · Cited by 110

Innovation-driven trend shaping COVID-19 vaccine development in China

Zhang, Y., Zhao, Y., Liang, H., Xu, Y. M., Zhou, C., Yao, Y., Wang, H., & Yang, X. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1034-6 · Cited by 2

Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variantPreprint

Knabl, L., Lee, H., Wieser, M., Mur, A., Zabernigg, A. F., Knabl, L., Rauch, S., Böck, M., Schumacher, J., Kaiser, N., et al. (2021) · medRxiv · doi:10.1101/2021.05.11.21256862 · Cited by 2

Defective ORF8 dimerization in delta variant of SARS CoV2 leads to abrogation of ORF8 MHC-I interaction and overcome suppression of adaptive immune responsePreprint

Chaudhari, A. M., Singh, I., Joshi, M. N., Patel, A. K., & Joshi, C. G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.24.457457 · Cited by 2

Emerging vaccine-breakthrough SARS-CoV-2 variantsPreprint

Wang, R., Chen, J., Hozumi, Y., Yin, C., & Wei, G. (2021) · PubMed · doi:10.48550/arxiv.2109.04509 · Cited by 7

Bioinformatic analysis of B and T cell epitopes from SARS-CoV-2 Spike, Membrane and Nucleocapsid proteins as a strategy to assess possible cross-reactivity between emerging variants, including Omicron, and other human coronavirusesPreprint

Pacheco-Olvera, D. L., Remy-Hernández, S. S., García-Valeriano, M. G., Rivera-Hernández, T., & López-Macías, C. I. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.16.480759 · Cited by 2

High-throughput molecular dynamics-based alchemical free energy calculations for predicting the binding free energy change associated with the common mutations in the spike receptor-binding domain of SARS-CoV-2Preprint

Bhadane, R. N., & Salo‐Ahen, O. M. H. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.07.483402 · Cited by 2

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamstersPreprint

Sun, W., Liu, Y., Amanat, F., González‐Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V. C., Lemus, N., Jangra, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.06.451301 · Cited by 2

Analysis of Whole-Genome Sequencing of SARS-CoV-2 Reveals Recurrent Mutations among Iranian PatientsPreprint

Abbasian, M. H., Mahdavi, B., Mahmanzar, M., Tokhanbigli, S., Sisakht, M. M., Moradi, B., & Rahimian, K. (2022) · medRxiv · doi:10.1101/2022.06.20.22276625 · Cited by 2

Exploring the Therapeutic Potential of Defective Interfering Particles in Reducing the Replication of SARS-CoV-2

Locke, M., Grebennikov, D. S., SAZONOV, I. A., López‐García, M., Loguinova, M. Y., Meyerhans, A., Bocharov, G. A., & Molina-Parı́s, C. (2024) · Mathematics · doi:10.3390/math12121904 · Cited by 1

Alveolar macrophage endosomal-lysosomal system: Potential therapeutic targets for COVID-19

Lan, Y., Wang, G., Wang, Z., Chen, Y., Gao, F., & He, W. (2025) · Animals and zoonoses. · doi:10.1016/j.azn.2025.03.002 · Cited by 1

Functional and Evolutionary Characterization of the NSP6 Protein in SARS-CoV-2 Omicron Variants

Souza, J. B., & Casseb, S. M. M. (2025) · SynBio · doi:10.3390/synbio3020007 · Cited by 1

Establishment of a Rapid Typing Method for Coronavirus Disease 2019 Mutant Strains Based on PARMS Technology

Gao, L., Zu, X., Liu, X., Yu, Z., Du, Z., Hu, Z., & Xue, Y. (2022) · Micromachines · doi:10.3390/mi13020145 · Cited by 1

Comparative Analysis of B.1.617.2 (Delta) Variant of SARS-CoV-2

Shahanshah, M. F. H., JAİN, S., Sharma, B., Grewall, A., & Swami, S. (2022) · Journal of Microbiology and Infectious Diseases · doi:10.5799/jmid.1086226 · Cited by 1

Fatores de virulência microbianos e terapias emergentes

Barbosa, A. V., da Silva, S. M., da Silva, F. H. S., de Assunção, M. A. S., & dos Anjos, F. B. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000093 · Cited by 2

Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1

Sidarovich, A., Krüger, N., Rocha, C., Graichen, L., Kempf, A. M., Nehlmeier, I., Lier, M., Cossmann, A., Stankov, M. V., Schulz, S. R., et al. (2022) · Viruses · doi:10.3390/v14112475 · Cited by 2

Employing T-Cell Memory to Effectively Target SARS-CoV-2

Tun, Z. H., Htike, N. T. T., Kyi‐Tha‐Thu, C., & Lee, W. (2023) · Pathogens · doi:10.3390/pathogens12020301 · Cited by 1

Computational design of a multi-epitope-based vaccine targeting the BF.7 Omicron variant of SARS-CoV-2

Raghavendra, B., Dhanushkumar, T., Selvam, P. K., Gopikrishnan, M., Doss, C. G. P., & Vasudevan, K. (2024) · Gene Reports · doi:10.1016/j.genrep.2024.101943 · Cited by 1

Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study

Zafilaza, K., Bellet, J., Truffot, A., Foulongne, V., Onambele, M. M., Salmona, M., Vellas, C., Périllaud-Dubois, C., Mirand, A., André‐Garnier, E., et al. (2024) · Viruses · doi:10.3390/v16101542 · Cited by 1

COVID-19: sudden and dramatic upsurge in the number of cases in India

Barot, K. S., Naik, S. H., Patel, M., Mankad, S., Patel, A. A., Pandya, P. S., Patel, V. V., & Nimbalkar, S. (2021) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20213047

Genomics and epidemiology of SARS-CoV-2 lineage

Sukegawa, S., & Takeuchi, H. (2021) · Uirusu · doi:10.2222/jsv.71.19 · Cited by 1

Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2

Singh, J., Ehtesham, N. Z., Hira, S., Shrestha, U. K., & Hasnain, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_8 · Cited by 1

Cell Entry and Unusual Replication of SARS-CoV-2

McCann, N. R., & Castellino, F. (2022) · Current Drug Targets · doi:10.2174/1389450124666221014102927 · Cited by 1

Multilocus adaptation to vaccinationPreprint

McLeod, D. V., & Gandon, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.01.446592 · Cited by 1

Unsupervised classification of SARS-CoV-2 genomic sequences uncovers hidden genetic diversity and suggests an efficient strategy for genomic surveillancePreprint

Chiara, M., Horner, D. S., Ferrandi, E., Gissi, C., & Pesole, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.23.449558 · Cited by 1

Single-shot rAAV5-based Vaccine Provides Long-term Protective Immunity against SARS-CoV-2 and Its VariantsPreprint

Liao, G., Fan, X., Lau, H., Liu, Z., Li, C., Xu, Z., Zhang, Y. L., Qi, X., Li, D., Zhu, Q. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.23.456471 · Cited by 1

An Interpretable Deep Learning Model for Predicting the Risk of Severe COVID-19 from Spike Protein SequencePreprint

Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Research Square · doi:10.21203/rs.3.rs-1234007/v1 · Cited by 1

Altered affinity to ACE2 and reduced Fc functional antibodies to SARS-CoV-2 RBD variantsPreprint

Haycroft, E. R., Davis, S. K., Ramanathan, P., López, E., Purcell, R. A., Tan, L. L., Pymm, P., Wines, B. D., Hogarth, P. M., Wheatley, A. K., et al. (2022) · medRxiv · doi:10.1101/2022.07.07.22277364 · Cited by 1

Vaccine Cocktail as a Future to Fight Against Family of SARS-Cov-19Preprint

Sharma, D., Sharotri, N., Kanchi, S., & Thakur, S. C. (2022) · Preprints.org · doi:10.20944/preprints202208.0204.v1

Structural and Computational Design of a SARS-2 Spike Antigen with Increased Receptor Binding Domain Exposure and Improved ImmunogenicityPreprint

Williams, J. A., Biancucci, M., Lessen, L. N., Tian, S., Balsaraf, A., Chen, L., Chesterman, C. C., Maruggi, G., Vandepaer, S., Huang, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.29.518231 · Cited by 1

COVID‐19: Virology

Najafi, S., Tofighi, S., & Sobczyk, J. (2022) · Wiley eBooks · doi:10.1002/9781119789741.ch2 · Cited by 1

Within-host evolution of SARS-CoV-2: how often are de novo mutations transmitted?Preprint

Korosec, C. S., Wahl, L. M., & Heffernan, J. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.08.552503 · Cited by 1

VirEvol platform : accurate prediction and visualization of SARS-CoV-2 evolutionary trajectory based on protein language model, structural information and immunological recognition mechanismPreprint

Zeng, X., Zhang, L., Ning, Z., Qiu, Y., Dong, R., Li, X., Lv, L., Xu, H., Wang, Y., & Ma, B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557978 · Cited by 1

Genomic evolution of SARS-CoV-2 variants of concern under in vitro neutralising selection pressure following two doses of the Pfizer-BioNTech BNT162b2 COVID-19 vaccinePreprint

Basile, K., Agius, J. E., Fong, W., McPhie, K. A., Fennel, M., Ko, D., Heuston, L., Lam, C., Arnott, A., Chen, S. C. ‐., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.24.558921 · Cited by 1

Rapid Emergence and Evolution of SARS-CoV-2 Variants in Advanced HIV InfectionPreprint

Ko, S. H., Radecki, P. E., Belinky, F., Bhiman, J. N., Meiring, S. T., Kleynhans, J., Amoako, D. G., Canedo, V. G., Lucas, M., Kekana, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.05.574420 · Cited by 1

Cytokine Storm Fatal Acute Kidney Infection Triggered by COVID-19 (SARS CoV-2) Infection: A ReviewPreprint

Regassa, H., Gudeta, K., Bhagat, A., & Chaturvedi, R. (2024) · Preprints.org · doi:10.20944/preprints202401.1910.v1

Alpha variant versus D614G strain in the Syrian hamster modelPreprint

Cochin, M., Lucıanı, L., Touret, F., Driouich, J., Petit, P.-R., Moureau, G., Baronti, C., Laprie, C., Thirion, L., Maes, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.19.440435

Broad neutralizing nanobody against SARS-CoV-2 engineered from pre-designed synthetic libraryPreprint

Liu, Q.-Y., Cai, C.-G., Huang, Y., Zhou, L., Guan, Y., Fu, S., Lin, Y.-H., Yang, T.-R., Liang, X.-H., Wang, N., et al. (2021) · bioRxiv · doi:10.1101/2021.08.07.455523

Coronavirus Pandemics Era and Cancer Patients

Tomás, M. (2021) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2021v67n4.2430

COVID-19 Pandemic: Analysis and Statistics of Confirmed Cases

Arceda, V. E. M., Arceda, M. A. M., & Laura, P. C. L. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98891

The Impact of SARS-CoV-2 Variants on Morbidity, Mortality and Effectiveness of Vaccines

Midilli, K. (2021) · Infectious Diseases and Clinical Microbiology · doi:10.36519/idcm.2020.0044

Memory Gaps in America: Mutational and Immunoinformatic Analysis of Evolving SARS-CoV-2 Variants of Concern and Interest

Shakran, D., Mikbel, D., Vilela, M. F., & Benoit, L. A. (2022) · ImmunoHorizons · doi:10.4049/immunohorizons.2100096

RELAÇÃO ESTRUTURA-ATIVIDADE DE FÁRMACOS ANTI-HIV DISPONIBILIZADOS PELO SISTEMA ÚNICO DE SAÚDE (SUS)

de Lira, M. F., de Melo, B. M. T., de Oliveira, L. L., Bezerra, C. D. O., Coutinho, F. N., & de Faria, A. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000107

DESAFIOS DO VÍRUS DA DENGUE NO MOSQUITO VETOR

Gonçalves, G. G. A., Feitosa, A. P. S., Brayner, F. A., & Alves, L. C. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000103

UMA BREVE ABORDAGEM DE LECTINA COM ATIVIDADE ANTI-SARS-CoV-2/COVID-19

Cintra, A. J. L., Torres‐León, C., Neves, J. L., & Correia, M. T. D. S. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000097

TERAPIAS ANTIVIRAIS: DA VACINA A NOVAS ABORDAGENS TERAPÊUTICAS

de Araújo, A. J. M., Bandeira, R. C. D. S., de Mélo, S. G. R., Calado, C. M. S. D. S., & Barbosa, A. V. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000109

COMO A TECNOLOGIA FARMACÊUTICA PODE AUXILIAR NO DESENVOLVIMENTO DE NOVOS MEDICAMENTOS ANTIVIRAIS? (PARTE 2)

da Costa, L. A. G., de Souza, C. G., Ferreira, A. S., de Araújo, L. V., Souza, A. T. M., & Neto, P. J. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000111

H1N1

Bernardo, R. N., Aguiar, M. A. M. D. S., Ferreira, A. L., & dos Santos, K. M. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000100

COVID-19: IMPORTÂNCIA E AVANÇOS NO DIAGNÓSTICO DA DOENÇA

da Rosa, M. M., Pereira, M. C., Cunha, E. G. C., Albuquerque, A. P. D. B., de Oliveira, P. S. S., Carvalho, L. V. D. N., Tavares, L. B., Costa, N. T. C., de Paula, S. K. S., de Carvalho, V. M. F., et al. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000094

ARBOVIROSES: ASPECTOS VIRAIS, ECOLÓGICOS, CLÍNICOS E EPIDEMIOLÓGICOS

de Oliveira, M. E. D. S. P., de Lima, M. V. D. S. A., de Assunção, M. A. S., & LIMA, V. K. D. A. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000102

CHIKUNGUNYA: DA EPIDEMIOLOGIA AO DESENVOLVIMENTO DE VACINAS

Purificação, A., Azevedo, E. D. A. N., Lins, R. D., & Viana, I. F. T. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000105

FATORES DE VIRULÊNCIA VIRAIS NA COVID-19

Farias, P. C. S., da Rocha, D. A. M., Feitosa, A. P. S., Alves, L. C., & Brayner, F. A. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000096

HEPATITE C

Caliari, V. D. A., Muniz, D. D. M., Cavalcanti, J. V. C., Saraiva, P. R. B. D. C., Arruda, A. T. C., Melo, J. V. A. S. N. D., Arruda, A. G. T. C., & Neto, J. R. D. E. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000108

CARACTERÍSTICAS CLÍNICAS DA COVID-19

da Rosa, M. M., Pereira, M. C., Pessoa-e-Silva, R., Sá, J. L. F., Silva, R. C., Mendonça, A. C. S., Lima, C. A. D. O., Ferreira, M. D. A., Rego, M. J. B. M., & Pitta, M. G. D. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000095

SARS-CoV-19 Mutations: is a Blessing or a Curse for Human Being?

Jadali, Z. (2022) · Ethiopian Journal of Health Sciences · doi:10.4314/ejhs.v32i2.28

Impacto de la variante de interés Mu en la pandemia de COVID-19 en Colombia

Peña-López, B. O., Velásquez-Martínez, M. C., & Rincón‐Orozco, B. (2022) · Salud UIS · doi:10.18273/saluduis.54.e:22060

Computational analysis of the novel Thailand-specific mutations in SARS-CoV-2 spike glycoprotein sequences

Chaisawasd, P., & Ittisoponpisan, S. (2022) · ScienceAsia · doi:10.2306/scienceasia1513-1874.2022.138

Studies on the enzymatic specificity of diguanylate cyclases domains and the production of new second messengers

Arévalo, S. J. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2022.tde-26102022-112347

Variants of Coronavirus and Cardiovascular Diseases

Dara, M., Saffar, M., Dianatpour, M., Tanideh, N., Azarpira, N., & Talebzadeh, M. (2022) · Frontiers in Medical Case Reports · doi:10.47746/fmcr.2022.3602

Sequence analysis of hot spot regions of spike and RNA‑dependent‑RNA polymerase (RdRp) genes of SARS-CoV-2 in Kerman, IranPreprint

Arefinia, N., Yaghobi, R., Ramezani, A., Farokhnia, M., & Sarvari, J. (2023) · Research Square · doi:10.21203/rs.3.rs-2658251/v1

Outbreak report of SARS-CoV-2 infection by airborne transmission: Epidemiologic and molecular evidence

Navas, M. C., Cerón, J. D., Aguilar-Jiménez, W., Rugeles, M. T., & Díaz, F. J. (2023) · Biomédica · doi:10.7705/biomedica.6695

Phyloepidemiology and adaptive evolution of SARS-CoV2 during the first and second wave of COVID-19 in India

Tewari, A., & Kumar, R. (2023) · Microbes Infection and Chemotherapy · doi:10.54034/mic.e1808

Identification of inhibitors against SARS-CoV-2 variants of concern using virtual screening and metadynamics-based enhanced sampling

Mandal, N., & Rath, S. L. (2023) · Chemical Physics · doi:10.1016/j.chemphys.2023.111995

Eficácia da heparina e do tocilizumabe na redução dos biomarcadores inflamatórios e trombóticos em pacientes idosos com infecção grave pela COVID-19

Neto, N. C. D. S. (2023) · doi:10.11606/t.5.2023.tde-22062023-145730

Investigation of SARS-CoV-2 IgG Binding Capability to Variants of the SARS-CoV-2 Virus

Johnson, L., Gascun, C. F. D., & Hassan, J. (2024) · Viral Immunology · doi:10.1089/vim.2024.0064

SARS-CoV-2 Mutations and Their Impacts on Virulence and Transmissibility of The Virus

Bahman, S., Farajnia, S., Alizadeh, E., Charoudeh, H. N., Hosseini, M. K., & Naghili, B. (2024) · ImmunoAnalysis · doi:10.34172/ia.4070

Spatiotemporal Dynamics of SARS-CoV-2 Variants During the First Year of the Pandemic Highlight the Earlier Emergence of the Zeta Variant of Interest in Brazil

Moraes, M. M., Campos, G. R. F., Banho, C. Á., Versiani, A. F., Santos, T. M. D., Parra, M. C. P., Lobl, E. E. D. O., Galvão, T. M., Vasilakis, N., & Nogueira, M. L. (2024) · Pathogens · doi:10.3390/pathogens13121069

Mathematical analysis of the COVID-19 pandemic dynamics in the emergence of resistant strains of SARS-CoV-2 in a vaccinated and non-vaccinated population: a real-world scenario in most countries

de León, U. A.-P., Pérez, Á. G. C., & Avila-Vales, E. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-44-328814-2.00009-6

Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults

Capão, A., de Araújo, M. F., Tort, L. F. L., Toledo, T. S., de Oliveira, A. C. A., Caetano, B. C., Resende, P. C., Martins‐Filho, O. A., Alves, M. R., Grifoni, A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126785

Within-Host Fitness and Antigenicity Shift Are Key Factors Influencing the Prevalence of Within-Host Variations in the SARS-CoV-2 S Gene

Xi, B., Hua, Z., Jiang, D., Chen, Z., Wei, J., Meng, Y.-H., & Du, H. (2025) · Viruses · doi:10.3390/v17030362

A Novel Antiviral Therapeutic Platform: Anchoring IFN-β to the Surface of Infectious Virions Equips Interferon-Evasive Virions with Potent Antiviral Activity

Jabbour, H., Bastian, A. G., DeOca, K. B., & Mannie, M. D. (2025) · Viruses · doi:10.3390/v17050697

Genomic Evolution of SARS-CoV-2 Variants of Concern Under In Vitro Neutralising Selection Pressure Following Two Doses of the Pfizer-BioNTech BNT162b2 COVID-19 Vaccine

Basile, K., Agius, J. E., Fong, W., McPhie, K. A., Fennel, M., Ko, D., Heuston, L., Lam, C., Arnott, A., Chen, S. C.-A., et al. (2025) · Viruses · doi:10.3390/v17091161 · Cited by 1

Epitope-driven polyfunctional divergence of SARS-CoV-2 RBD antibodies

Rosenbaum, P., Planchais, C., Bruel, T., Beretta, M., Staropoli, I., Bolland, W., Guivel‐Benhassine, F., Planas, D., French COVID Cohort Study Group, CORSER Study Group, et al. (2026) · iScience · doi:10.1016/j.isci.2026.117345

Newly Emerging Variants of SARS-CoV-2

Safdar, M., Özaslan, M., Junejo, Y., Younas, U., Ahmad, M. Z., Bibi, J., & Noreen, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815322194125010008

Tracking down the origin and subsequent spread of SARS-CoV-2 lineage B.1.619

Bollen, N., Hong, S. L., Potter, B. I., Lienhard, R., Tritten, M.-L., Sierro, N., Guedj, E., Dulize, R., Bornand, D., Auberson, M., et al. (2025) · Virus Evolution · doi:10.1093/ve/veaf017

What Has SARS-CoV-2 Taught Us About Evolution?

Liu, Y. (2025) · Cureus · doi:10.7759/cureus.94502 · Cited by 1

A novel fusion protein of COVID-19 virus enhancing protection of Syrian hamsters infected with SARS-CoV-2

Wang, H., Yang, T., Yan, Y., Yang, F., Song, X., Zhang, S., Jiang, W., Li, M., Sun, W., Li, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.027 · Cited by 1

Variant-Specific Diagnosis of COVID-19

Bhattacharjee, M., Kumar, S., & Ghosh, M. K. (2025) · Medical virology · doi:10.1007/978-981-95-1426-7_8

Elucidating the link between NS-SNP-Induced protein conformational changes and drug resistance in Klebsiella pneumoniae

Liu, W., & Rao, X. (2026) · Archives of Microbiology · doi:10.1007/s00203-025-04697-2

The role of O-GlcNAcylation in the pathophysiology of Systemic Lupus Erythematosus

Galli, G. (2022) · theses.fr (ABES) · doi:10.70675/db863337z7c69z4a5dz9e94z7163b54542ee

The mechanisms and consequences of SARS-CoV-2 induced cell-to-cell fusion

Bolland, W. (2024) · theses.fr (ABES) · doi:10.70675/37becb05zce46z4760z8c80zee5762b9dcea

Navigating key mutations in RBD and SARS-CoV-2 epitope classification: Enhancing antibody therapeutic development amidst evolving challenges

Alexsius, K., Amin, I. M., Yunus, N. M., Mydin, R. B. S. M. N., Aris, F., & Zakaria, N. A. (2026) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2026.034.2.02

Disulfide bonds stabilize the SARS-CoV-2 RBD and preserve binding to ACE2 following thermal denaturation

McCann, N. R., & Castellino, F. (2026) · Bioscience Reports · doi:10.1042/bsr20260440

Genomic surveillance of COVID-19 in Hong Kong (2020–2023): Analysing SARS-CoV-2 variants, mutations, and their impact on viral entry

Pilapil, J. D., Mata, M. A., del Rosario, R., Pasciolco, M. J., Chow, K. L., & YEUNG, K. (2026) · Epidemiology and Infection · doi:10.1017/s0950268826102040

Hydrophobic remodeling of the SARS-CoV-2 RBD large loop attenuates ACE2 engagement and viral fitness

Wang, A., Guo, H., Yang, H., Chen, H., Imojara, A., Ju, B., Zhang, Z., & Yan, R. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014742

Characterization of SARS-CoV-2 Spike mutations

Schotsaert, M. (2025) · ImmPort · doi:10.21430/m301eut53a

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination seraPreprint

Jangra, S., Ye, C., Rathnasinghe, R., Stadlbauer, D., PVI study group, Krammer, F., Simon, V. R., Martínez‐Sobrido, L., García‐Sastre, A., & Schotsaert, M. (2021) · medRxiv · doi:10.1101/2021.01.26.21250543 · Cited by 133

Neutralizing response against E484K variant after original SARS-CoV-2 infectionPreprint

Hayashi, T., Yaegashi, N., & Konishi, I. (2021) · medRxiv · doi:10.1101/2021.05.07.21256803

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628

Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage

Álvarez-Díaz, D. A., Laiton‐Donato, K., Torres, O., Ruiz-Moreno, H. A., Franco-Muñoz, C., Beltran, M. A., Mercado, M., Rueda, M. G., & Muñoz, A. L. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198629 · Cited by 8

Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies

Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 101